Does oxypentifylline reduce the intensity of acute graft-versus-host disease following allogeneic bone marrow transplantation?

Haematologia

Volumn 28, Issue 1, 1996, Pages 45-51

  Ghosh, K ^a   Hutchinson, R M ^b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

bone marrow transplantation; GVHD; oxypentifylline

Indexed keywords

PENTOXIFYLLINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THEOBROMINE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029802043     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Antin, J. H., Ferrara, L. M.: Cytokine dysregulation and acute graft versus host disease. Blood 80, 2964-2968 (1992).
2. Holler, E., Kolb, H. J., Moller, A., Kempeni, J., Liesenfield, S., Pechumer, H., Lehmacher, W., Rucjdeschel, G., Gleixmer, B., Riedner, C., Ledderose, G., Grehm, G., Mittermuller, J., Wilmanns, W.: Increased levels of tumour necrosis factor alpha precedes major complications of bone marrow transplantation. Blood 75, 1101-1016 (1990).
3. Han, J., Thompson, P., Bentler, B.: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumour necrosis factor synthesis at separate points in signalling pathway. J. Exp. Med. 172, 391-394 (1990).
4. Sullivan, G. W., Carper, H. T., Novick, W. J., Mandell, G. L.: Inhibition of inflammatory action of interleukin-1 and tumour necrosis factor (alpha) on neutrophil function by pentoxifylline. Infec. Immunol. 56, 1722-1729 (1988).
5. Bianco, J. A., Appelbaum, F. R., Nemunaitis, J., Almgren, J., Andrews, F., Kettner, P., Shields, A., Singer, J.: Phase I-II trial of pentoxifylline for the prevention of transplant related toxicities following bone marrow transplantation. Blood 78, 1205-1211 (1991).
6. Van der Jagt, R. H. C., Pari, G., McDiarmid, S. A., Boisvert, O. M., Huesbsch, L. B.: Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplantation 13, 203-207 (1994).
7. Glucksberg, H., Storb, R., Fefer, A., Buckner, C. D., Neiman, P. E., Clift, R. A., Lerner, K. G., Thomas, E. D.: Clinical manifestation of graft vs host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18, 295-304 (1974).
8. Altman, D. G.: Practical Statistics for Medical Research. 1st edn, Chapman & Hall, London (1991).
9. Fahr, A., Langer, R., Ziegoleit, S.: Influence of pentoxifylline administered in vivo on synthesis of prostacyclin in human varicose veins. Biomed. Bioclin. Acta 14, 29-34 (1988).
10. Görög, P., Kovács, I. B.: Prostacyclin is a more potent stimulator of thrombolysis than inhibitor of hemostasis. Hemostasis 26, 337-342 (1986).
11. Tilg, H., Eibl, D., Pichl, M., Gachter, A., Harold, M., Brankova, J., Huber, C., Niederwieser, D.: Immune response modulation by pentoxifylline in vitro. Transplantation 56, 196-201 (1993).
12. Attal, M., Huguet, F., Ruble, H., Charlet, J. P., Schlaifer, D., Hyunh, A., Laurent, G., Pris, J.: Prevention of regimen related toxicities after bone marrow transplantation by pentoxifylline: a prospective randomised trial. Blood 82, 732-736 (1993).
13. Clift, R. A., Bianco, J. A., Applebaum, F. R., Buckner, C. D., Singer, J. W., Bakke, L., Bensinger, W. I., Bowden, R. A., McDonald, G. B., Schubert, M., Shields, A. F., Slattey, J. T., Storb, R., Fisher, L. D., Mori, M., Thomas, E. D., Hansen, J. A.: A randomised control trial for the prevention of regimen related toxicities in patients undergoing allogeneic bone marrow transplantation. Blood 82, 2025-2030 (1992).